Full Name
Dr. Paola Neri MD, PhD
Job Title
Associate Professor/Oncology
Company/Affiliation
University of Calgary
Speaker Bio
Dr. Paola Neri, MD, PhD, is an Associate Professor of Medicine, attending physician in the Hematology Division at the University of Calgary, and member of the Arnie Charbonneau Cancer Institute. Since January 2019, she is the Scientific Director of the Cancer Translational Research Core, a clinically accredited laboratory located at the Arthur Child Comprehensive Cancer Center in Calgary.
Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy, in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy, in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003–2006, she was a Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA, under the mentorship of Dr. Kenneth Anderson. In June 2008, she joined the University of Calgary.
The main focus of her research is the study of multiple myeloma (MM), with a particular interest in genomic studies, with the goal of identifying mechanisms of drug resistance and discovering novel therapeutic targets for this incurable disease. Dr. Neri is well published in the field and has received national and international grants from several agencies, including the International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, and Canadian Institutes of Health Research (CIHR).
In 2019, she received the Engineered Air Chair (research funds) in Cancer Research from the University of Calgary. In 2021, she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her important translational work in multiple myeloma. In 2025, she received the Global Impact in Myeloma Research Award from the Canadian Myeloma Research Group (CMRG).
She is currently a member of the American Society of Hematology, co-chair of the Charbonneau Research & Innovation Committee in Calgary, and a member of the Blood Editorial Board, and is very active in both preclinical and clinical trial research in myeloma.
Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy, in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy, in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003–2006, she was a Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA, under the mentorship of Dr. Kenneth Anderson. In June 2008, she joined the University of Calgary.
The main focus of her research is the study of multiple myeloma (MM), with a particular interest in genomic studies, with the goal of identifying mechanisms of drug resistance and discovering novel therapeutic targets for this incurable disease. Dr. Neri is well published in the field and has received national and international grants from several agencies, including the International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, and Canadian Institutes of Health Research (CIHR).
In 2019, she received the Engineered Air Chair (research funds) in Cancer Research from the University of Calgary. In 2021, she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her important translational work in multiple myeloma. In 2025, she received the Global Impact in Myeloma Research Award from the Canadian Myeloma Research Group (CMRG).
She is currently a member of the American Society of Hematology, co-chair of the Charbonneau Research & Innovation Committee in Calgary, and a member of the Blood Editorial Board, and is very active in both preclinical and clinical trial research in myeloma.
Speaking At
